Associated Papers
Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.
Yuan R et al.
Annals of Hematology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E et al.
Cancer Treatment Reviews, 2026
Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1.
Zeng T et al.
Acta Pharmaceutica Sinica. B, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.
Nindra U et al.
Cancer Treatment and Research Communications, 2026
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.
Anastacio Da Costa Carvalho L et al.
Cancer Immunology Research, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Epidemiological survey of potential familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii.
Takaoka K et al.
International Journal of Hematology, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways.
Caputo C et al.
Molecular Therapy. Oncology, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Hollis RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.
Abel HJ et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept.
Kang Z et al.
Molecular and Cellular Pediatrics, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.
Chatterjee A et al.
Biorxiv : the Preprint Server for Biology, 2025
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
Haraguchi E et al.
International Journal of Cancer, 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Undifferentiated Melanoma: A Clinicopathologic and Gene Expression Analysis Study With Identification of HMGA2 as a Diagnostic Marker.
Fischer GM et al.
The American Journal of Surgical Pathology, 2025
MUTE-Seq: An Ultrasensitive Method for Detecting Low-Frequency Mutations in cfDNA With Engineered Advanced-Fidelity FnCas9.
Ye S et al.
Advanced Materials (deerfield Beach, Fla.), 2025
Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
Li Y et al.
British Journal of Haematology, 2025
Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.
Tawel HM et al.
Cureus, 2025
Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer.
Yeh C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia.
Zhou W et al.
Blood Cancer Journal, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Umeda M et al.
Blood, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.
Yu H et al.
Leukemia, 2025
The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.
Aboelmaaty S et al.
Annals of Surgical Oncology, 2025
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia.
Sommer C et al.
Scientific Reports, 2025
Unveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.
Ferrari A et al.
International Journal of Molecular Sciences, 2025
Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.
Soloveva M et al.
International Journal of Molecular Sciences, 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis.
Nann D et al.
The Journal of Pathology. Clinical Research, 2025
Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.
Wang Y et al.
The British Journal of Dermatology, 2025
Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution.
Yang B et al.
Virchows Archiv : an International Journal of Pathology, 2025
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.
Kok CH et al.
Blood Advances, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations.
Kojitani Y et al.
Oncology Letters, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Identification of Genetic Variants Using Next-Generation Sequencing in Pediatric Myelodysplastic Syndrome: From Disease Biology to Clinical Applications.
Lovatel VL et al.
International Journal of Molecular Sciences, 2025
Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.
Yoshimura F et al.
Cancer Reports (hoboken, N.j.), 2025